AC
BBLG

Armistice Capital’s Bone Biologics BBLG Stock Holding History

Armistice Capital’s Portfolio BBLG Stock Details BBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,167
Closed -$78.8K – 270
2024
Q1 		$78.8K Buy
+6,167
New +$120K ﹤0.01% 312

Other funds holding BBLG

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
MWA
MFA Wealth Advisors Pittsburgh, Pennsylvania $587M AUM 27.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital's BBLG Position: Q2 2024 in Review

Armistice Capital sold out of Bone Biologics (BBLG) in Q2 2024, closing a stake of 6,167 shares — an estimated $78.8K sold.

Armistice Capital first reported a position in BBLG in Q1 2024 and held it in 1 quarter. The position peaked at $78.8K in Q1 2024. 5 funds tracked by Wall St. Rank hold BBLG as of Q2 2024.

  • Armistice Capital reported no remaining Bone Biologics position as of Q2 2024 after selling out during the quarter.
  • Armistice Capital sold 6,167 Bone Biologics shares in Q2 2024, an estimated $78.8K.
  • Armistice Capital first reported a position in Bone Biologics in Q1 2024 and held it in 1 quarter.
  • Armistice Capital's Bone Biologics position peaked at $78.8K in Q1 2024.
  • 5 funds tracked by Wall St. Rank held Bone Biologics as of Q2 2024.

Based on Armistice Capital's 13F filing for Q2 2024, filed 14 Aug 2024.